Here are 35 books that The Billion-Dollar Molecule fans have personally recommended if you like
The Billion-Dollar Molecule.
Shepherd is a community of 12,000+ authors and super readers sharing their favorite books with the world.
Frank S. David, MD, PhD leads the biopharma consulting firm Pharmagellan, where he advises drug companies and investors on R&D and business strategy. He is also an academic researcher on strategy, regulation, and policy in the drug industry; a member of the Harvard-MIT Center for Regulatory Science; and a former blogger at Forbes.com.
Since Nixon’s "War on Cancer," oncology treatment has seen some great advances, but also the approval of scores of over-priced drugs that do little to improve patients’ quality or quantity of life. Oncologist Vinay Prasad has written a broad, accessible overview of the flaws of modern cancer drug development that spans clinical trial design, conflicts of interest, regulatory policy, and more. His unabashedly anti-pharma stance gets preachy in places, but most of the challenges he identifies are spot-on and provide a thought-provoking roadmap for the future.
How hype, money, and bias can mislead the public into thinking that many worthless or unproven treatments are effective.
Each week, people read about new and exciting cancer drugs. Some of these drugs are truly transformative, offering major improvements in how long patients live or how they feel-but what is often missing from the popular narrative is that, far too often, these new drugs have marginal or minimal benefits. Some are even harmful. In Malignant, hematologist-oncologist Dr. Vinayak K. Prasad writes about the many sobering examples of how patients are too often failed by cancer policy and by how oncology…
I am the former president of Pfizer Global Research, where I led research groups around the globe in finding new medicines to treat cancer, addiction, AIDS, immunological diseases, and pain. After retiring from Pfizer, I have been closely involved with biotech companies that also are seeking breakthrough drugs. This industry is a crucial part of the healthcare ecosystem, as evidenced by the remarkable response and, ultimately, the crushing of the COVID-19 pandemic. Yet, it is not just underappreciated but is treated with scorn by many. This booklist provides sources from which the reader can gain a full understanding of the value of the biopharmaceutical industry, the challenges it faces, and its importance to the world’s health.
Legislators and healthcare insurers are seeking ways to slash healthcare costs, often focusing on cutting the costs of medicines through schemes like price controls. Yet, drugs make up only about 13 percent of the money paid on healthcare. This book does a great job of explaining what is behind the pricing of new drugs but, more importantly, shows that all life-saving drugs eventually become low-cost generics – truly a Great American Drug Deal.
This book scrutinizes all players in the healthcare industry and offers new ideas for cost-saving measures, such as closing loopholes, dealing with bad actors, and educating consumers. If you want to understand how best to balance innovation and affordability, this book is a must-read.
Developing life-changing drugs is risky and expensive—but that’s not what makes them unaffordable.Drug pricing is a staple of every news cycle and political debate. And while we’ve struggled for decades to agree on solutions that serve all patients without jeopardizing the invention of new medicines, many Americans suffer because they can’t afford the drugs they need.Do we really have to choose between affordability and innovation?In The Great American Drug Deal, scientist and industry expert Peter Kolchinsky answers this question with a decisive No. The pharmaceutical industry’s commitment to creating new lifesaving drugs destined to become inexpensive generics can be balanced…
Frank S. David, MD, PhD leads the biopharma consulting firm Pharmagellan, where he advises drug companies and investors on R&D and business strategy. He is also an academic researcher on strategy, regulation, and policy in the drug industry; a member of the Harvard-MIT Center for Regulatory Science; and a former blogger at Forbes.com.
A key issue about drug pricing not covered in Kolchinsky's book relates to value: even if a new therapy is affordable, is it "worth it"? Health economist Peter Neumann and his colleagues have written an authoritative, insightful, and extremely accessible history of efforts to align drugs' prices with their benefits to patients and society. This is a must-read guide for both insiders and non-experts to a topic that will be at the forefront of the drug pricing debate in the coming decade.
The US prescription drug business is a $500 billion industry whose rising prices carry profound consequences for patients, caregivers, employers and taxpayers across the nation. In the United States, average prices of leading brand-name drugs are two to four times higher than prices charged in other wealthy countries, raising questions as to what Americans are getting for the extra expense. On the other hand, healthy industry returns have arguably fueled life-saving innovation. With the advent of ever more targeted and powerful treatments, including cell- and gene-based therapies with multi-million-dollar price tags, the need for sensible drug pricing policies will only…
In my younger days, as the son of a medical professor and a public health nurse, I was more interested in healing society than patients. But my political interests and research agenda as a professor of political science ultimately led back to medicine. I found that profit-maximizing market competition in health care failed miserably to promote value in therapeutics and economize on society’s scarce resources. I became aware of the neglect of public health to prevent disease for vulnerable groups in society and save money as well as lives. Pervasive and enduring economic conflicts of interest in the medical-industrial complex bear primary responsibility for severe deficits in quality, equality, and economy in American health care.
I found, as a history buff, The Struggle for Drug Reform to be an eye-opener about how America’s exceptionally high drug prices among other deficits in health care quality and coverage resulted from the past exercise of power by the pharmaceutical industry, the lynchpin of America’s “medico-industrial complex.”
I was impressed by historian Tobbell’s meticulously researched account of the industry’s strategic alliances with self-interested medical scientists, not just conservative political forces, and its use of anti-communist propaganda to fight off the threat of drug pricing regulations.
I personally found important her discussions of how the industry allied with the American Medical Association against universal health care, against FDA demands for evidence about drug efficacy and safety before allowing drugs on the market, and against the threat to its profits from generic drugs.
Since the 1950s, the American pharmaceutical industry has been heavily criticized for its profit levels, the high cost of prescription drugs, drug safety problems, and more, yet it has, together with the medical profession, staunchly and successfully opposed regulation. "Pills, Power, and Policy" offers a lucid history of how the American drug industry and key sectors of the medical profession came to be allies against pharmaceutical reform. It details the political strategies they have used to influence public opinion, shape legislative reform, and define the regulatory environment of prescription drugs. Untangling the complex relationships between drug companies, physicians, and academic…
I am an economist who came to realize that the marketplace of ideas was a political doctrine, and not an empirical description of how we came to know what we think we know. Science has never functioned in the same manner across centuries; it was only during my lifetime that it became recast as a subset of market reality. I have spent a fair amount of effort exploring how economics sought to attain the status of a science; but now the tables have turned. It is now scientists who are trained to become first and foremost market actors, finally elevating the political dominance of the economists.
A best-seller in the UK, it never garnered the attention it deserved in the US. As a trained physician, Goldacre explains why doctors cannot trust the information concerning prescription drugs that is made available to them, and why this should concern every patient. The incentives motivating drug regulators constitute a big part of the problem, but the actual conduct of clinical trials comes in for intensive scrutiny as well. The rigors of double-blinded trials are useless if owners of the data can hide whatever outcomes they don’t like. His chapter on how to bend a clinical trial has become a classic.
"Smart, funny, clear, unflinching: Ben Goldacre is my hero." ―Mary Roach, author of Stiff, Spook, and Bonk
We like to imagine that medicine is based on evidence and the results of fair testing and clinical trials. In reality, those tests and trials are often profoundly flawed. We like to imagine that doctors who write prescriptions for everything from antidepressants to cancer drugs to heart medication are familiar with the research literature about these drugs, when in reality much of the research is hidden from them by drug companies. We like to imagine that doctors are impartially educated, when in reality…
In my younger days, as the son of a medical professor and a public health nurse, I was more interested in healing society than patients. But my political interests and research agenda as a professor of political science ultimately led back to medicine. I found that profit-maximizing market competition in health care failed miserably to promote value in therapeutics and economize on society’s scarce resources. I became aware of the neglect of public health to prevent disease for vulnerable groups in society and save money as well as lives. Pervasive and enduring economic conflicts of interest in the medical-industrial complex bear primary responsibility for severe deficits in quality, equality, and economy in American health care.
I find Angell’sThe Truth About the Drug Companies extremely valuable for teaching students about how the pharmaceutical industry translates high profits into power resources to protect and increase those profits over time.
The former New England Journal of Medicine editor exposed how drug companies enlist politicians, the FDA, and medical academia for their cause. And armies of lawyers to extend monopoly marketing rights for years.
It was my first introduction to how they spend more on marketing than research, much of that on “copy-cat” drugs of dubious superiority to ones with expired patents.
As a tax (and high drug price) payer, I was disturbed to learn how they use government funds for basic research and then rig and spin their reporting of clinical studies to inflate their products’ therapeutic value and underplay their risks.
During her two decades at The New England Journal of Medicine, Dr. Marcia Angell had a front-row seat on the appalling spectacle of the pharmaceutical industry. She watched drug companies stray from their original mission of discovering and manufacturing useful drugs and instead become vast marketing machines with unprecedented control over their own fortunes. She saw them gain nearly limitless influence over medical research, education, and how doctors do their jobs. She sympathized as the American public, particularly the elderly, struggled and increasingly failed to meet spiraling prescription drug prices. Now, in this bold, hard-hitting new book, Dr. Angell exposes…
Everybody knows that all animals—bats, bears, sharks, ponies, and people—start out as a single cell: the fertilized egg. But how does something no bigger than the period at the end of this sentence give rise to the remarkable complexity of each of these creatures?
I am peculiar. Really. I’m an autistic, non-binary, PhD historian who writes weird non-fiction books—and I read them, too. Among my friends are folks like Mary Roach (Fuzz, Stiff, Bonk, Gulp), Deborah Blum (Poisoner’s Handbook), and Ed Yong (I contain Multitudes, An Immense World). Yet, despite there being so many amazing books about strange facts, it's still hard to find them in one place. Your average bookstore doesn’t have a “peculiar” section, for some reason. That’s why I started myPeculiar Book ClubYouTube show: I wanted there to be a home for authors and readers of the quirky, quizzical, curious, and bizarre. And then I thought, hey, why not make a book list, too.
Two pharmacists sit in a Boston courtroom accused of murder. The weapon: a fungus. The death count: 100 and rising. These facts set the stage for a true-crime thriller by investigative journalist Jason Dearen, and it has the makings of a horror movie. There’s scientific hubris, sketchy ethics, a cover-up, and a monster, too: a slimy, sticky, fungal mold that infected patients and began eating their brains alive. It’s riveting, packed with information about how fungal spores managed to contaminate a medical supply chain, and frankly hard to put down. I have done my share of forensic research, and never have I encountered killer fungus before; I consider this an unmissable book.
An award-winning investigative journalist's horrifying true crime story of America's deadliest drug contamination outbreak and the greed and deception that fueled it.
Two pharmacists sit in a Boston courtroom accused of murder. The weapon: the fungus Exserohilum rostratum. The death count: 100 and rising. Kill Shot is the story of their hubris and fraud, discovered by a team of medical detectives who raced against the clock to hunt the killers and the fungal meningitis they'd unleashed.
"Bloodthirsty" is how doctors described the fungal microbe that contaminated thousands of drug vials produced by the New England Compounding Center (NECC). Though NECC…
In my younger days, as the son of a medical professor and a public health nurse, I was more interested in healing society than patients. But my political interests and research agenda as a professor of political science ultimately led back to medicine. I found that profit-maximizing market competition in health care failed miserably to promote value in therapeutics and economize on society’s scarce resources. I became aware of the neglect of public health to prevent disease for vulnerable groups in society and save money as well as lives. Pervasive and enduring economic conflicts of interest in the medical-industrial complex bear primary responsibility for severe deficits in quality, equality, and economy in American health care.
If you think that medical journals published by respected medical societies are full of good science, think again.
For me, Abramson’s Sickeningnailed the case for a conclusion that the net effect of the many hundreds of medical journals published here and around the world is to subtract from the sum of human medical knowledge.
Abramson, as an expert witness in criminal and civil cases against drug companies, draws in part on subpoenaed documents to expose how medical science, as part of the entire medical-industrial complex, is corrupted from start to finish by the drug industry’s funding of most clinical trials, their control over the data analysis, and even their ghost-writing of articles submitted to journals.
New and disturbing was the withholding of clinical trials’ raw data from journals’ peer reviewers. Instead, they get biased summaries bearing drug manufacturers’ fingerprints.
The inside story of how Big Pharma’s relentless pursuit of ever-higher profits corrupts medical knowledge—misleading doctors, misdirecting American health care, and harming our health.
The United States spends an excess $1.5 trillion annually on health care compared to other wealthy countries—yet the amount of time that Americans live in good health ranks a lowly 68th in the world. At the heart of the problem is Big Pharma, which funds most clinical trials and therefore controls the research agenda, withholds the real data from those trials as corporate secrets, and shapes most of the information relied upon by health care professionals.…
I’ve always been in love with the idea of love. I didn’t know what that feeling was like for a long time–not being in love myself–so I grew attached to fictionalised worlds that brought those ideas to life. I’ve always been the person who smiles at a meet-cute or feels that warm, fuzzy feeling inside when the couple you’ve been rooting for the last two hundred pages finally kisses. I want them to know how exciting it can be to feel loved and experience that through the creation of stories. This is why romance is, and likely always will be, a huge thematic influence on all forms of my work.
A gut-wrenching but provokingly beautiful story that highlights an illness that isn’t spoken much about in fiction.
The relationship between Stella and Will is such a heartbreakingly warming story that gives the reader a new-found understanding of how cystic fibrosis can impact an individual's life. I enjoy reading stories involving new, important conversations that need to be had, especially on topics we don’t often see in novels.
I think it’s important for writing to help spread awareness. It’s something that I myself want to do more in my own work.
Also a major motion picture starring Cole Sprouse and Haley Lu Richardson! Goodreads Choice Winner, Best Young Adult Fiction of 2019
In this #1 New York Times bestselling novel that’s perfect for fans of John Green’s The Fault in Our Stars, two teens fall in love with just one minor complication—they can’t get within a few feet of each other without risking their lives.
Can you love someone you can never touch?
Stella Grant likes to be in control—even though her totally out of control lungs have sent her in and out of the hospital most of her life. At…
Most people know the slowburn romance. A spark flickers at deliberate pace until finally passion ignites. But what about the slowburn mystery? As a reader and a writer, I’m drawn to mysteries that twine as a well-drawn character, usually an amateur sleuth, gets pulled into investigating some eerie event. These mysteries begin with a straightforward query, and as the sleuth digs, the mystery grows. The pace leaves room for well-developed subplots—often, in my favorites, a slowburn romance, too. I love a book where I can settle into the world while the story gathers steam. And in the end, when that slow flame finally blazes… Oh, it’s so worth the wait.
In All That’s Left To Say, dual timelines braid threads of a mystery together in a way that allowed me to contrast Hannah then and now and wonder not just about the mystery Hannah’s trying to solve, but about how she became the master sleuth she thinks she needs to be to get answers.
This contrast, as much as the mystery, drew me into the story and had me turning pages every time we jumped between past and present. Of course, the enemies-to-friends-to-lovers romance also helped. How Lord imbued a single tie-straightening scene with more sexual tension than most kissing scenes might be the biggest mystery in this book.
Hannah MacLaren has grown up between two worlds: scraping by happily with her single, working mum and avoiding the Maryland upper crust in the next town over, where her wealthy cousin and best friend Sophie lives. The plan is to get out: Hannah from paycheck-to-paycheck life, and Sophie from the cosseted world she doesn't fit into.
But just before junior year begins, something goes horribly wrong. Sophie overdoses at a party, leaving behind a shocked community and bereft best friends. As the haze of grief begins to clear, Hannah teams up with Sophie's other best friend, Gabi, to find out…
